Bristol-Myers Squibb Rises 4.37% In 3 Days As Technicals Signal Breakout Potential
Generated by AI AgentAinvest Technical Radar
Friday, Jul 11, 2025 6:30 pm ET2min read
BMY--
Bristol-Myers Squibb (BMY) concluded its most recent session with a 1.80% gain, marking its third consecutive advance and bringing its three-day total return to 4.37%. This upward momentum reflects renewed buyer interest, but comprehensive technical indicators must be evaluated to assess the sustainability and potential trajectory of this move.
Candlestick Theory
The recent three-day rally formed a small ascending pattern (not a classic "Three White Soldiers" due to modest gains) closing near session highs, indicating controlled bullish momentum. Key resistance is evident at $48.60–48.61 (July 10 high), which capped advances on July 2 and July 8. Support now resides near $46.98–47.00 (July 10 low and July 9 close), coinciding with the 50-day moving average, reinforcing its technical significance. A decisive break above $48.61 may trigger further upside, while failure here could invite consolidation.
Moving Average Theory
The 50-day MA (approximating ~$47.80) recently crossed above the 100-day MA (~$48.50), signaling improving medium-term momentum ("Golden Cross" potential). However, price remains below the declining 200-day MA (~$52.10), confirming the long-term downtrend since the April 2025 peak. Current price trades above the 50-day MA, suggesting short-term support aligns with the recent bullish candlestick structure. The converged 50/100-day MAs near $48.00 now act as a pivotal zone.
MACD & KDJ Indicators
The MACD histogram turned positive in early July, with the signal line crossing above zero, confirming bullish momentum acceleration. The KDJ oscillator shows the %K line (78) above %D (68), trending upward from oversold territory in May without divergence. While approaching overbought territory, neither oscillator shows signs of bearish reversal, supporting near-term upside continuation potential.
Bollinger Bands
Bands contracted notably in late June, preceding the current volatility expansion phase. Price now tests the upper band (~$48.60), aligning with the $48.61 horizontal resistance. Sustained trading above the upper band would signal exceptional strength, while a rejection here may imply a reversion to the midline (~$47.30). Band width expansion supports the likelihood of continued directional movement.
Volume-Price Relationship
Volume surged during the July 1 rally (21.1M shares, +2.64%), validating the breakout above $47.50 resistance. Subsequent gains saw above-average volume (14.7M shares on July 10 vs. 30-day avg. ~13M), confirming buyer conviction. The absence of climactic volume spikes suggests accumulation rather than exhaustion, supporting trend sustainability.
Relative Strength Index (RSI)
The 14-day RSI (currently ~62) exited oversold territory (<30) in mid-May and now approaches neutral. It respected the 40-support level during June pullbacks, reflecting intact momentum. While nearing overbought thresholds (>70), current readings imply room for further upside before warnings materialize. No bearish divergence is evident versus price action.
Fibonacci Retracement
Using the major downtrend from the April 10 high ($63.34) to the May 14 low ($44.12), key retracement levels are: 38.2% ($51.38), 50% ($53.73), and 61.8% ($56.08). The recent rally stalled near the 23.6% retracement ($48.82), aligning precisely with the $48.60–48.61 resistance zone. A decisive breach targets the 38.2% level ($51.38).
Confluence & Divergence
Significant confluence exists at $48.60–48.61, where horizontal price resistance, the upper Bollinger Band, and the 23.6% Fibonacci level converge. A breakout above this zone, validated by supportive MACD, KDJ, and volume, may catalyze further gains toward $51.38. The primary divergence lies between short-term bullish MA crosses and the still-declining 200-day MA, reflecting conflicting medium/long-term signals. No bearish momentum divergences are currently detected.
Conclusion
Bristol-Myers Squibb shows strengthening short-term bullish momentum, validated by volume and oscillators. The critical $48.60–48.61 resistance represents the immediate test; a decisive close above this zone may trigger acceleration toward the $51.38 Fibonacci level. However, the long-term downtrend (evidenced by the 200-day MA slope) warrants caution, and failure at resistance could see retracement toward the 50/100-day MA confluence (~$47.80–48.00). The technical setup currently favors a breakout attempt, supported by volume and momentum confluence.
Bristol-Myers Squibb (BMY) concluded its most recent session with a 1.80% gain, marking its third consecutive advance and bringing its three-day total return to 4.37%. This upward momentum reflects renewed buyer interest, but comprehensive technical indicators must be evaluated to assess the sustainability and potential trajectory of this move.
Candlestick Theory
The recent three-day rally formed a small ascending pattern (not a classic "Three White Soldiers" due to modest gains) closing near session highs, indicating controlled bullish momentum. Key resistance is evident at $48.60–48.61 (July 10 high), which capped advances on July 2 and July 8. Support now resides near $46.98–47.00 (July 10 low and July 9 close), coinciding with the 50-day moving average, reinforcing its technical significance. A decisive break above $48.61 may trigger further upside, while failure here could invite consolidation.
Moving Average Theory
The 50-day MA (approximating ~$47.80) recently crossed above the 100-day MA (~$48.50), signaling improving medium-term momentum ("Golden Cross" potential). However, price remains below the declining 200-day MA (~$52.10), confirming the long-term downtrend since the April 2025 peak. Current price trades above the 50-day MA, suggesting short-term support aligns with the recent bullish candlestick structure. The converged 50/100-day MAs near $48.00 now act as a pivotal zone.
MACD & KDJ Indicators
The MACD histogram turned positive in early July, with the signal line crossing above zero, confirming bullish momentum acceleration. The KDJ oscillator shows the %K line (78) above %D (68), trending upward from oversold territory in May without divergence. While approaching overbought territory, neither oscillator shows signs of bearish reversal, supporting near-term upside continuation potential.
Bollinger Bands
Bands contracted notably in late June, preceding the current volatility expansion phase. Price now tests the upper band (~$48.60), aligning with the $48.61 horizontal resistance. Sustained trading above the upper band would signal exceptional strength, while a rejection here may imply a reversion to the midline (~$47.30). Band width expansion supports the likelihood of continued directional movement.
Volume-Price Relationship
Volume surged during the July 1 rally (21.1M shares, +2.64%), validating the breakout above $47.50 resistance. Subsequent gains saw above-average volume (14.7M shares on July 10 vs. 30-day avg. ~13M), confirming buyer conviction. The absence of climactic volume spikes suggests accumulation rather than exhaustion, supporting trend sustainability.
Relative Strength Index (RSI)
The 14-day RSI (currently ~62) exited oversold territory (<30) in mid-May and now approaches neutral. It respected the 40-support level during June pullbacks, reflecting intact momentum. While nearing overbought thresholds (>70), current readings imply room for further upside before warnings materialize. No bearish divergence is evident versus price action.
Fibonacci Retracement
Using the major downtrend from the April 10 high ($63.34) to the May 14 low ($44.12), key retracement levels are: 38.2% ($51.38), 50% ($53.73), and 61.8% ($56.08). The recent rally stalled near the 23.6% retracement ($48.82), aligning precisely with the $48.60–48.61 resistance zone. A decisive breach targets the 38.2% level ($51.38).
Confluence & Divergence
Significant confluence exists at $48.60–48.61, where horizontal price resistance, the upper Bollinger Band, and the 23.6% Fibonacci level converge. A breakout above this zone, validated by supportive MACD, KDJ, and volume, may catalyze further gains toward $51.38. The primary divergence lies between short-term bullish MA crosses and the still-declining 200-day MA, reflecting conflicting medium/long-term signals. No bearish momentum divergences are currently detected.
Conclusion
Bristol-Myers Squibb shows strengthening short-term bullish momentum, validated by volume and oscillators. The critical $48.60–48.61 resistance represents the immediate test; a decisive close above this zone may trigger acceleration toward the $51.38 Fibonacci level. However, the long-term downtrend (evidenced by the 200-day MA slope) warrants caution, and failure at resistance could see retracement toward the 50/100-day MA confluence (~$47.80–48.00). The technical setup currently favors a breakout attempt, supported by volume and momentum confluence.

Si he logrado llegar a ciertos lugares, fue gracias al apoyo de aquellos que han tenido un gran impacto en mi camino hacia el éxito.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet